LitAlert ~~ GeneLit.com

    • Synthetic lethality on drug discovery: an update on cancer therapy.
    • Yar MS, Haider K, Gohel V, Siddiqui NA, Kamal A.
    • Expert Opin Drug Discov. 2020 Mar 31:1-10. doi: 10.1080/17460441.2020.1744560. [Epub ahead of print]
    • Review
    • BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.
    • Jacot W, Lopez-Crapez E, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, Chartron E, Theillet C, Lemoine A, Saffroy R, Lamy PJ, Guiu S.
    • Cancers (Basel). 2020 Mar 30;12(4). pii: E828. doi: 10.3390/cancers12040828.
    • Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status.
    • Keung MY, Wu Y, Badar F, Vadgama JV.
    • J Clin Med. 2020 Mar 30;9(4). pii: E940. doi: 10.3390/jcm9040940.
    • Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy.
    • Pellini F, Granuzzo E, Urbani S, Mirandola S, Caldana M, Lombardi D, Fiorio E, Mandarà M, Pollini GP.
    • Breast Care (Basel). 2020 Feb;15(1):14-20. doi: 10.1159/000501711. Epub 2019 Sep 13.
    • International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts.
    • Thomssen C, Lüftner D, Untch M, Haidinger R, Würstlein R, Harbeck N, Augustin D, Briest S, Ettl J, Fasching PA, Förster F, Kurbacher CM, Lück HJ, Marschner N, Müller L, Müller V, Perlova-Griff L, Radke I, Ruckhäberle E, Scheffen I, Schumacher-Wulf E, Schwoerer M, Steinfeld-Birg D, Ziegler-Löhr K.
    • Breast Care (Basel). 2020 Feb;15(1):82-95. doi: 10.1159/000505957. Epub 2020 Feb 10.